skip to Main Content

We are developing

Tomorrow’s immuno – modulators oncology therapy
A single platform for defeating cancer and much more.

We are HEPHAISTOS-Pharma

A preclinical stage Biotech company developing the next generation of oncology treatments that will be boost immune system to treat incurable cancers.

One need, one mission :

Immunotherapy has shown impressive results in the past 5 years by treating cancers like never seen before. Unfortunately, success level are still very low and only 10% of patients can be cured today.

Our mission is to take Immunotherapy to the next level of efficiency by stimulating patients immune response and turning hidden cold tumors into hot targets for our immune system.


International experts & experimented operational team


Chairwoman & CSO

Martine CAROFF
DSc., Inventor, TLR4 agonist biochemistry expert. EU Woman Innovators Prize 2019.



Frederic CAROFF
MSc Centrale Paris, MBA Essec, Biotech Manager, Industrial scale up expert


CMC Manager

PhD, Head of Research Ability. Chemistry and Mass Spectrometry expert.

Jerome-Kerzerho-NB-190x190 (1)

Preclinical plan Manager

PhD, Immunologist, Immuno-oncology expert.

Business Developer

Simon PICO
PhD, MBA EMLyon, Biotech Ecosystem expert, Business Angel

Advisory Board


Pr. Charles DUMONTET,
Deputy Director CRCL Physician in Hematology. Oncology KOL.

Pr. of Hematology in University of Lyon Deputy Director CRCL Physician in
Hematology. Oncology KOL.


Dr. Robert S. Munford, Medical Doctor at NIH

Antibacterial Host Defense specialist.


Dr. Nathalie Garçon, CEO/CSO BIOASTER,

Former GSK Vaccines VP, Adjuvant KOL. research


Dr. Joel Crouzet,
Former CEO of InnaVirVax,

clinical stage vaccine and cancer
immunotherapy expert.

Market Needs

Turning cold tumors into hot tumors

Only 10% of current immunotherapies are successful
Need for stronger and safer immuno-modulators
to turn cold tumors into hot tumors and improve cancer therapy

Innovation & advantages

Onco-Boost platform

ONCO-Boost is the Fisrt-In-Class Immunostimulant injectable intravenous able to treat metastatic and hardly accessible cancer like Osteorcoma

Mechanism of Action

Mechanism of Action (MoA)


will stimulate monocytes, and dendritic cells to recruit and mature other immune defenses like CD4 T Cells, CD8 T Cells and macrophages.

Antibody (mAb)

will block friendly recognition pathways between Tumor cells and host Cells allowing immune defenses to see Tumor as a target to destroy.

All together

By recruiting and stimulating immune cells, ONCO-Boost enable treatment of tumors that were not previously sensitive to mAb’s action and open the way to treat incurable cancers.


Immuno Oncology

ONCO-Boost Immunotherapy

Human Vaccine

VAXI-Boost natural adjuvant


University Paris Saclay

HEPHAISTOS-Pharma was present at the Event organized by…

Read more

Come in we’re hiring

HEPHAISTOS is currently hiring a Preclinical Development Manager,…

Read more

European Grant

HEPHAISTOS-Pharma obtained a European Grant for its development…

Read more

WILCO startup cluster

HEPHAISTOS-Pharma was selected by WILCO startup cluster to…

Read more

Clusters & Partners


HEPHAISTOS-Pharma is financed by the European Union FEDER regional fund

HEPHAISTOS-Pharma is financed by the WILCO Healthcare startup cluster.

HEPHAISTOS-Pharma is financed by the European Union and aims at becoming a breakthrough innovative Biotech in oncology, reaching clinical Phase 1 within 2 years. The ONCO-Boost project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 868937

HEPHAISTOS-Pharma’s academic partner CRCL is financed by the Region Auvergne-Rhône-Alpes, the Grand Lyon Metropole and the CLARA Canceropole.






Back To Top